Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity

Uzma Naz Shaikh; Muhammad Ali Ghoto; Abdullah Dayo; Mudassar Iqbal Arain; Rabia Parveen

doi:doi:10.11648/j.plm.20220601.11

| Peer-Reviewed

Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity

Uzma Naz Shaikh, Muhammad Ali Ghoto, Abdullah Dayo, Mudassar Iqbal Arain, Rabia Parveen

Published in Pathology and Laboratory Medicine (Volume 6, Issue 1)

Received: 12 January 2022 Accepted: 14 February 2022 Published: 28 February 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Hypothyroidism and obesity both are medical conditions that have been connected closely. 6- Propyl-2-thiouracil (PTU) is an anti-thyroid drug usually used to treat overactive thyroid, but may cause obesity, which rises morbidity and mortality of patients. Object To explore the prevalence of obesity in hypothyroid patients, who were receiving PTU for the management of overactive thyroid. The aims of current research to access the drug utilization and investigation of PTU which aids in attaining rational therapy and other aspects related to patient’s safety. Method: A cross-sectional research was conducted and 200 participants with overactive thyroid selected by non-probably consecutive sampling method from POD #4 at Liaquat University of Medical and Health Sciences, Hospital, Jamshoro from May 2016 to April 2017 and all adults with overactive thyroid receiving Propylthiouracil were included. Their Thyroid function tests performed on Immunoassay Elecysis 2010 and entire data was evaluated via SPSS version 22.0. Result: The data revealed that the PTU-induced obesity in 52 hypothyroid patients (n=14 males, n=38 females) and the prevalence of PTU-induced obesity was 26.0%. Conclusion: It was perceived that PTU alters the function of thyroid stimulating hormone (TSH) or thyrotropin and increases the amount of thyrotropin would will be secondary to obesity.

Published in	Pathology and Laboratory Medicine (Volume 6, Issue 1)
DOI	10.11648/j.plm.20220601.11
Page(s)	1-6
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Hyperthyroidism, Hypothyroidism, Obesity, Propylthiouracil

References

[1]	Torlinska B et al, treatment for hyperthyroidism increase the risk of obesity in some patients: Clinical Thyroidology for the Public March 2020; 13 (3): 3-4.
[2]	Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr. 2000; 71 (6): 1421–32.
[3]	Danforth E, Jr, Horton ES, O'Connell M, Sims EA, Burger AG, Ingbar SH, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest. 1979; 64 (5): 1336–47.
[4]	Biondi B. Thyroid and obesity: An intriguing relationship. J Clin Endocrinol Metab. 2010; 95: 3614–7.
[5]	Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab. 2006; 91: 3088–91.
[6]	Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362: 906–16.
[7]	WHO. Report of a WHO Consultation on Obesity. Geneva, Switzerland: World Health Organisation; 1998. Obesity: preventing and managing the global epidemic.
[8]	Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab. 2002; 87 (2): 489-99.
[9]	Hassan M. Al-Musa. Impact of Obesity on Serum Levels of Thyroid Hormones among Euthyroid Saudi Adults, J Thyroid Res. 2017; 2017: 5739806.
[10]	Mónica Ríos-Prego, Luis Anibarro, and Paula Sánchez-Sobrino, Relationship between thyroid dysfunction and body weight: a not so evident paradigm, Int J Gen Med. 2019; 12: 299–304.
[11]	Rose, Ashley, "Elevated TSH and Obesity: Cause or Consequence?" (2019). Nursing Capstones. 139.
[12]	Laurberg P. Knudsen N. Andersen S. Carlé A. Pedersen I. B. Karmisholt J. Thyroid function and obesity. Eur Thyroid J 2012; 1: 159–167.
[13]	Yingying Wang, Xiaolian Dong, Chaowei Fu, Meifang Su, Feng Jiang et al, Thyroid stimulating Hormone (TSH) is associated with General and abdominal obesity: A cohort study in school-aged Girls during puberty in East China, Front. Endocrinol., 30 September 2020 \| https://doi.org/10.3389/fendo.2020.00620.
[14]	Caroline S. Fox, MD, MPH; Michael J. Pencina, PhD; Ralph B. D’Agostino, PhD; et, Relation of Thyroid function to body weight: Cross-sectional and longitudinal observations in a community-base sample. Arch Intern Med. 2008; 168 (6): 587-592.
[15]	Madani K. A., Al-Amoudi N. S., Kumosani T. A. The state of nutrition in Saudi Arabia. Nutrition and Health. 2000; 14 (1): 17–31.

Cite This Article

Plain Text BibTeX RIS

APA Style

Uzma Naz Shaikh, Muhammad Ali Ghoto, Abdullah Dayo, Mudassar Iqbal Arain, Rabia Parveen. (2022). Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathology and Laboratory Medicine, 6(1), 1-6. https://doi.org/10.11648/j.plm.20220601.11

Copy | Download

ACS Style

Uzma Naz Shaikh; Muhammad Ali Ghoto; Abdullah Dayo; Mudassar Iqbal Arain; Rabia Parveen. Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathol. Lab. Med. 2022, 6(1), 1-6. doi: 10.11648/j.plm.20220601.11

Copy | Download

AMA Style

Uzma Naz Shaikh, Muhammad Ali Ghoto, Abdullah Dayo, Mudassar Iqbal Arain, Rabia Parveen. Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathol Lab Med. 2022;6(1):1-6. doi: 10.11648/j.plm.20220601.11

Copy | Download

@article{10.11648/j.plm.20220601.11,
  author = {Uzma Naz Shaikh and Muhammad Ali Ghoto and Abdullah Dayo and Mudassar Iqbal Arain and Rabia Parveen},
  title = {Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity},
  journal = {Pathology and Laboratory Medicine},
  volume = {6},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.plm.20220601.11},
  url = {https://doi.org/10.11648/j.plm.20220601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.plm.20220601.11},
  abstract = {Hypothyroidism and obesity both are medical conditions that have been connected closely. 6- Propyl-2-thiouracil (PTU) is an anti-thyroid drug usually used to treat overactive thyroid, but may cause obesity, which rises morbidity and mortality of patients. Object To explore the prevalence of obesity in hypothyroid patients, who were receiving PTU for the management of overactive thyroid. The aims of current research to access the drug utilization and investigation of PTU which aids in attaining rational therapy and other aspects related to patient’s safety. Method: A cross-sectional research was conducted and 200 participants with overactive thyroid selected by non-probably consecutive sampling method from POD #4 at Liaquat University of Medical and Health Sciences, Hospital, Jamshoro from May 2016 to April 2017 and all adults with overactive thyroid receiving Propylthiouracil were included. Their Thyroid function tests performed on Immunoassay Elecysis 2010 and entire data was evaluated via SPSS version 22.0. Result: The data revealed that the PTU-induced obesity in 52 hypothyroid patients (n=14 males, n=38 females) and the prevalence of PTU-induced obesity was 26.0%. Conclusion: It was perceived that PTU alters the function of thyroid stimulating hormone (TSH) or thyrotropin and increases the amount of thyrotropin would will be secondary to obesity.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity
AU  - Uzma Naz Shaikh
AU  - Muhammad Ali Ghoto
AU  - Abdullah Dayo
AU  - Mudassar Iqbal Arain
AU  - Rabia Parveen
Y1  - 2022/02/28
PY  - 2022
N1  - https://doi.org/10.11648/j.plm.20220601.11
DO  - 10.11648/j.plm.20220601.11
T2  - Pathology and Laboratory Medicine
JF  - Pathology and Laboratory Medicine
JO  - Pathology and Laboratory Medicine
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2640-4478
UR  - https://doi.org/10.11648/j.plm.20220601.11
AB  - Hypothyroidism and obesity both are medical conditions that have been connected closely. 6- Propyl-2-thiouracil (PTU) is an anti-thyroid drug usually used to treat overactive thyroid, but may cause obesity, which rises morbidity and mortality of patients. Object To explore the prevalence of obesity in hypothyroid patients, who were receiving PTU for the management of overactive thyroid. The aims of current research to access the drug utilization and investigation of PTU which aids in attaining rational therapy and other aspects related to patient’s safety. Method: A cross-sectional research was conducted and 200 participants with overactive thyroid selected by non-probably consecutive sampling method from POD #4 at Liaquat University of Medical and Health Sciences, Hospital, Jamshoro from May 2016 to April 2017 and all adults with overactive thyroid receiving Propylthiouracil were included. Their Thyroid function tests performed on Immunoassay Elecysis 2010 and entire data was evaluated via SPSS version 22.0. Result: The data revealed that the PTU-induced obesity in 52 hypothyroid patients (n=14 males, n=38 females) and the prevalence of PTU-induced obesity was 26.0%. Conclusion: It was perceived that PTU alters the function of thyroid stimulating hormone (TSH) or thyrotropin and increases the amount of thyrotropin would will be secondary to obesity.
VL  - 6
IS  - 1
ER  -

Copy | Download

Author Information

Uzma Naz Shaikh

Department of Pharmaceutics, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan
Muhammad Ali Ghoto

Department of Pharmacy Practice, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan
Abdullah Dayo

Department of Pharmaceutics, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan
Mudassar Iqbal Arain

Department of Pharmacy Practice, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan
Rabia Parveen

Department of Pharmacy Practice, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Uzma Naz Shaikh, Muhammad Ali Ghoto, Abdullah Dayo, Mudassar Iqbal Arain, Rabia Parveen. (2022). Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathology and Laboratory Medicine, 6(1), 1-6. https://doi.org/10.11648/j.plm.20220601.11

Copy | Download

ACS Style

Uzma Naz Shaikh; Muhammad Ali Ghoto; Abdullah Dayo; Mudassar Iqbal Arain; Rabia Parveen. Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathol. Lab. Med. 2022, 6(1), 1-6. doi: 10.11648/j.plm.20220601.11

Copy | Download

AMA Style

Uzma Naz Shaikh, Muhammad Ali Ghoto, Abdullah Dayo, Mudassar Iqbal Arain, Rabia Parveen. Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity. Pathol Lab Med. 2022;6(1):1-6. doi: 10.11648/j.plm.20220601.11

Copy | Download

@article{10.11648/j.plm.20220601.11,
  author = {Uzma Naz Shaikh and Muhammad Ali Ghoto and Abdullah Dayo and Mudassar Iqbal Arain and Rabia Parveen},
  title = {Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity},
  journal = {Pathology and Laboratory Medicine},
  volume = {6},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.plm.20220601.11},
  url = {https://doi.org/10.11648/j.plm.20220601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.plm.20220601.11},
  abstract = {Hypothyroidism and obesity both are medical conditions that have been connected closely. 6- Propyl-2-thiouracil (PTU) is an anti-thyroid drug usually used to treat overactive thyroid, but may cause obesity, which rises morbidity and mortality of patients. Object To explore the prevalence of obesity in hypothyroid patients, who were receiving PTU for the management of overactive thyroid. The aims of current research to access the drug utilization and investigation of PTU which aids in attaining rational therapy and other aspects related to patient’s safety. Method: A cross-sectional research was conducted and 200 participants with overactive thyroid selected by non-probably consecutive sampling method from POD #4 at Liaquat University of Medical and Health Sciences, Hospital, Jamshoro from May 2016 to April 2017 and all adults with overactive thyroid receiving Propylthiouracil were included. Their Thyroid function tests performed on Immunoassay Elecysis 2010 and entire data was evaluated via SPSS version 22.0. Result: The data revealed that the PTU-induced obesity in 52 hypothyroid patients (n=14 males, n=38 females) and the prevalence of PTU-induced obesity was 26.0%. Conclusion: It was perceived that PTU alters the function of thyroid stimulating hormone (TSH) or thyrotropin and increases the amount of thyrotropin would will be secondary to obesity.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Propylthiouracil: An Intriguing Connection Among the Propylthiouracil, Hypothyroidism, and Obesity
AU  - Uzma Naz Shaikh
AU  - Muhammad Ali Ghoto
AU  - Abdullah Dayo
AU  - Mudassar Iqbal Arain
AU  - Rabia Parveen
Y1  - 2022/02/28
PY  - 2022
N1  - https://doi.org/10.11648/j.plm.20220601.11
DO  - 10.11648/j.plm.20220601.11
T2  - Pathology and Laboratory Medicine
JF  - Pathology and Laboratory Medicine
JO  - Pathology and Laboratory Medicine
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2640-4478
UR  - https://doi.org/10.11648/j.plm.20220601.11
AB  - Hypothyroidism and obesity both are medical conditions that have been connected closely. 6- Propyl-2-thiouracil (PTU) is an anti-thyroid drug usually used to treat overactive thyroid, but may cause obesity, which rises morbidity and mortality of patients. Object To explore the prevalence of obesity in hypothyroid patients, who were receiving PTU for the management of overactive thyroid. The aims of current research to access the drug utilization and investigation of PTU which aids in attaining rational therapy and other aspects related to patient’s safety. Method: A cross-sectional research was conducted and 200 participants with overactive thyroid selected by non-probably consecutive sampling method from POD #4 at Liaquat University of Medical and Health Sciences, Hospital, Jamshoro from May 2016 to April 2017 and all adults with overactive thyroid receiving Propylthiouracil were included. Their Thyroid function tests performed on Immunoassay Elecysis 2010 and entire data was evaluated via SPSS version 22.0. Result: The data revealed that the PTU-induced obesity in 52 hypothyroid patients (n=14 males, n=38 females) and the prevalence of PTU-induced obesity was 26.0%. Conclusion: It was perceived that PTU alters the function of thyroid stimulating hormone (TSH) or thyrotropin and increases the amount of thyrotropin would will be secondary to obesity.
VL  - 6
IS  - 1
ER  -

Copy | Download